Metabolon Lands $14,999,980 Series E Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7f112a93-43c6-42d7-868a-9397fefeb308 - Date
12/31/2013 - Company Name
Metabolon - Mailing Address
617 Davis Dr. Durham, NC 27713 USA - Company Description
Metabolon has quickly become a leader in the discovery of biomarkers using metabolomics. Located in Research Triangle Park, North Carolina, Metabolon is based in a biotechnology epicenter. - Website
http://www.metabolon.com - Transaction Type
Venture Equity - Transaction Amount
$14,999,980 - Transaction Round
Series E - Proceeds Purposes
Proceeds will support the recent launch by Metabolon’s partner, Bostwick Laboratories, of Prostarix(TM), a urine-based test that provides important metabolic information on the likelihood that a patient with slightly elevated PSA scores has prostate cancer, thus confirming the need to proceed to biopsy. The funds will also be used for the continued development of Quantose(TM) IGT, Metabolon’s surrogate test for oral glucose tolerance, as well as its test for the recurrence of bladder cancer. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
